Terrestrial Bio Appoints Marella Thorell as Chief Financial and Business Officer
BOSTON, November 17, 2026 — Terrestrial Bio, Inc., a biotech company transforming the delivery of next-generation therapies, today announced the appointment of Marella Thorell as Chief Financial and Business Officer.
“We are thrilled to welcome Marella to the Terrestrial team. Her proven track record building financial and operational infrastructures and teams at fast-growing, publicly traded biotech companies will be instrumental in helping Terrestrial advance its clinical programs and scale manufacturing,” said Rachel Sha, CEO of Terrestrial Bio. "I look forward to partnering with Marella to drive strategic financing and potential partnerships, to support advancement of our lead program, VX-201, and to position Terrestrial’s Tacterra™ platform for long-term growth."
Ms. Thorell brings to Terrestrial decades of executive leadership in the biotech community. Her expertise spans capital strategy and execution, financial planning and reporting, corporate transactions, and the management of corporate functions. She joins Terrestrial from Seres Therapeutics, where she served as Executive Vice President and Chief Financial Officer and also held the role of Co-President and CEO. Previously, she was Chief Financial Officer of Evelo Biosciences, Chief Accounting Officer at Centessa Pharmaceuticals, Chief Financial Officer of Palladio Biosciences, and Chief Financial Officer and Chief Operating Officer of Realm Therapeutics. She has also served on the boards of Carisma Therapeutics, ESSA Pharma and Vallon Pharmaceuticals.
“Terrestrial is focused on a challenge that is incredibly important to patients, namely, making powerful therapies simpler to receive and easier to fit into everyday life,” said Ms. Thorell. “I am excited to join this talented team who have generated promising clinical data, built unique manufacturing capabilities, and attracted committed investors. In my new role, I will focus on building the company’s capabilities, and leading capital strategy, and formation of strategic partnerships intended to enable Terrestrial’s next stage of growth and create value for patients and other stakeholders.”
At Terrestrial, Ms. Thorell will lead the company’s financial, operational, business development, and corporate services functions, supporting the clinical development and manufacturing expansion as it advances its proprietary Tacterra™ microarray patch platform, starting with GLP-1 delivery.
This executive appointment follows the achievement of several key milestones for Terrestrial in 2026. In March, the company announced completion of a $50 million Series C financing. In July, Terrestrial announced that it had dosed the first participants in a Phase 1 clinical trial evaluating VX-201, its investigational Tacterra™ microarray patch for semaglutide delivery. In October, the company opened its new Boston headquarters and manufacturing facility, designed to support clinical trial supply and demonstrate commercial-scale production for VX-201.
About Terrestrial Bio, Inc.
Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1.
Terrestrial's proprietary Tacterra™ microarray patch (MAP) and applicator platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes. Once applied, each patch delivers bioactive tips into the skin, which dissolve quickly into the body, rapidly releasing their therapeutic payload. Designed for self-administration, the temperature-stable Tacterra™ platform enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.
Terrestrial has generated strong clinical and in-vivo proof of concept across multiple molecules. For more information, visit www.terrestrialbio.com.


